Japan Bronchopulmonary Dysplasia Treatment Market and Forecast 2020-2026

                                          
About Bronchopulmonary Dysplasia(Facts, Figures & Treatment):
 As per an article from WHO, more than 15 million babies are born prematurely worldwide. Also, an estimated 10,000 to 15,000 newborns develop BPD in the United States every year. This correlates to about 1 in 10 births. Premature birth can lead to apnea and bronchopulmonary dysplasia, a condition that interferes with lung development and may eventually cause asthma or early onset emphysema in those born prematurely.

Bronchopulmonary dysplasia (BPD) is a form of chronic lung disease that affects newborns. Most infants who develop BPD have been born prematurely and need oxygen therapy. Most infants recover from BPD, but some may have long-term breathing difficulties. In BPD the lungs and the airways (bronchi) are damaged, causing tissue destruction (dysplasia) in the tiny air sacs of the lung (alveoli).

In the lungs, BPD causes damage to the current and developing alveoli. Additionally, the tiny blood vessels surrounding the alveoli may be affected, making the passage of blood through the lungs more difficult. The lower the number of working alveoli, the longer the infant may need to remain on a ventilator, which can cause further damage to the child’s lungs. As the lungs of a newborn  are particularly vulnerable, high amounts of inhaled oxygen and pressure may overstretch the alveoli, causing inflammation and damage to the inside lining of the airways, the alveoli and the blood vessels around them. These effects are particularly damaging on the premature lung. BPD is considered to be primarily a complication of prematurity. Although, different conditions may affect the growth of the fetus during the pregnancy and may also lead to premature labor. Prenatal infections or maternal complications such as smoking, drug use, placental abnormalities (preeclampsia) and inflammation of the fetal membranes (chorioamnionitis) may cause BPD.

The degree of prematurity in an infant is largely what puts a child at risk of developing BPD. A majority of newborns who develop BPD are born more than 10 weeks early, weigh less than two pounds at birth, and are born with breathing problems. BPD is rare in infants born after 32 weeks of pregnancy.

In the long run, increased pressure inside the blood vessels in the lungs and between the heart and lungs can cause pulmonary hypertension. In severe cases, heart failure can occur. Newborns who suffer from BPD may also experience trouble feeding, leading to delayed development.

Caffeine is beneficial in preventing and treating apnea and bronchopulmonary dysplasia in newborns, improving the quality of life of premature infants. The caffeine citrate injection, used for apnea of the premature newborn, was initially approved by the FDA in 1999.

The global Bronchopulmonary Dysplasia Drug market is valued at million US$ in 2020 is expected to reach million US$ by the end of 2029, growing at a CAGR of during 2021-2029.

Market Analysis and Insights: Global Bronchopulmonary Dysplasia Treatment Market

This report focuses on Global Bronchopulmonary Dysplasia Treatment market.

The Japan Bronchopulmonary Dysplasia Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.

Japan Bronchopulmonary Dysplasia Treatment Scope and Market Size

Bronchopulmonary Dysplasia Treatment market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Bronchopulmonary Dysplasia Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2015-2026.

Segment by Type, the Bronchopulmonary Dysplasia Treatment market is segmented into

 	
Stem Cell Drugs
 	
Other

Segment by Application, the Bronchopulmonary Dysplasia Treatment market is segmented into

 	
Newborns and Babies

Regional and Country-level Analysis

The Bronchopulmonary Dysplasia Treatment market is analysed and market size information is provided by regions (countries).

The key regions covered in the Bronchopulmonary Dysplasia Treatment market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.

The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

Competitive Landscape and Bronchopulmonary Dysplasia Treatment Market Share Analysis

Bronchopulmonary Dysplasia Treatment market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Bronchopulmonary Dysplasia Treatment business, the date to enter into the Bronchopulmonary Dysplasia Treatment market, Bronchopulmonary Dysplasia Treatment product introduction, recent developments, etc.

The major vendors covered:

 	
Meridigen Biotech
 	
Airway Therapeutics
 	
Gennisium Pharma
 	
Bedford Pharmaceuticals
 	
Hikma Pharmaceuticals USA Inc.
 	
Chiesi Farmaceutici SpA
 	
Sun Pharmaceutical Industries Ltd
 	
Exela Pharma Sciences, Llc.
 	
Fresenius Kabi USA, LLC
 	
AuroMedics Pharma LLC
 	
Armas Pharmaceuticals Inc.
 	
Time Cap Labs, Inc
 	
Amerisource Bergen

Key Developments and Approval for Bronchopulmonary Dysplasia Drug in 2020

In August 2020,Gennisium Pharma received marketing authorization valid throughout the European Union for Gencebok which is a stimulant medicine used for treating apnoea of prematurity, a condition in which babies born prematurely stop breathing for longer than 20 seconds. Gencebok contains the active substance caffeine citrate. Gencebok is a hybrid medicine, containing the same active substance, but at a different strength. The reference medicine for Gencebok is Peyona. Apnoea in premature babies occurs because the part of the babys brain that controls breathing (breathing centre) is not fully developed. Caffeine citrate, the active substance in Gencebok, blocks the effect of adenosine. Adenosine is a natural substance that slows down the activity of some parts of the brain including the breathing centre. By reducing the effect of adenosine, caffeine citrate stimulates the brain to restore breathing. Gennisium also granted exclusive licence to Reach-Pharma for Gencebok® in Australia, New-Zealand and Papua-New Guinea. Additionally, Gennisium expanded its presence in the most important markets in Latin America, Mexico and Brazil, in granting exclusive promotion rights to Moksha8 for Gencebok®
Caffeine Citrate Injection (the generic equivalent of Hikma's, CAFCIT®), available in 60mg/3mL; has an approximate market size of $4M, annually.